HUMA
insider transactionsHumacyte, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 2 different insiders made open-market purchases in the last 90 days, totalling $59.8K.
Net shares · 90d
-24.0K
67.8K buy · 91.8K sell
Net value · 90d
-$22.5K
$59.8K in · $82.3K out
Sentiment · 90d
Net selling
42% buying · 58% selling
Open-market trades · 90d
4
67.8K buy · 91.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Susan Richards Windham-Bannister
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Laura E Niklason KEY
President, CEO and Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
0 sh
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Grant·A
Director
$0
80.0K sh
Own New
-
Buy·P
Director
$50.0K
56.8K sh · $0.88
Own +62%
-
Sell·S
Chief Medical Officer · 10b5-1
$41.1K
45.9K sh · $0.90
Own -14%
-
Sell·S
Dale A. Sander KEY
CFO and Chief Corp. Dev. Off · 10b5-1
$41.1K
45.9K sh · $0.90
Own -15%
-
Buy·P
Director
$9.8K
11.0K sh · $0.89
Own +33%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Susan Richards Windham-Bannister | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Max N. Wallace | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Laura E Niklason KEY | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Kathleen Sebelius | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Keith Anthony Jones | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Diane Seimetz | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Charles Bruce Green | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Brady W Dougan | Grant A | 0 | $0 |
| Jun 11, 2026 | Michael T. Constantino | Grant A | 80.0K | $0 |
| Jun 11, 2026 | Emery N. Brown | Grant A | 80.0K | $0 |
| Jun 11, 2026 | John Philip Bamforth | Grant A | 80.0K | $0 |
| May 19, 2026 | Kathleen Sebelius | Buy P | 56.8K | $50.0K |
| May 18, 2026 | Shamik J Parikh 10b5-1 | Sell S | 45.9K | $41.1K |
| May 18, 2026 | Dale A. Sander KEY 10b5-1 | Sell S | 45.9K | $41.1K |
| May 18, 2026 | Michael T. Constantino | Buy P | 11.0K | $9.8K |
About HUMA insider trading
This page tracks insider transactions for Humacyte, Inc. (HUMA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.